Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 300,000 incentive stock options to consultants. The incentive stock options have an exercise price of $0.40 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the second tranche of its non-brokered private placement (the “Private Placement”) raising gross proceeds of $341,735 by the issuance of 1,667,000 units at a price of $0.205 per unit.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the first tranche of its non-brokered private placement (the “Private Placement”) raising gross proceeds of $633,655.00 by the issuance of 3,091,000 units at a price of $0.205 per unit.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company (“units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) announces that, subject to the approval of the TSX Venture Exchange (the “Exchange”), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has provided the following update on projects in progress.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company’) (TSXV: APC) (FSE: 0E8), is pleased to announce that Dr. Benjamin Krantz will be joining the Company’s US subsidiary Advanced Proteome Therapeutics Inc. (“APTI”) as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board of directors after.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is providing an update on its radioimaging and biodistribution study.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 1,575,000 incentive stock options to directors, officers, and consultants. The incentive stock options have an exercise price of $0.11 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has provided the following update on projects in progress.